-transparent.png){kind=logo}
Solubility measurements, seeded crystal growth kinetics, solution depletion adsorption studies, nucleation observations, zeta potential measurements, and measurements of in vivo intrarenal crystallization all failed to show that either oxipurinol or allopurinol riboside interacts with calcium, oxalate, or whewellite (CaC2O4.H2O) at concentrations expected in therapeutic situations. We conclude that at therapeutically expected concentrations, oxipurinol and allopurinol riboside do not affect crystallization of calcium oxalate.
Related Publications
B Finlayson, and
J Burns, and
A Smith, and
L Du Bois
January 1986,
Advances in experimental medicine and biology,
B Finlayson, and
J Burns, and
A Smith, and
L Du Bois
May 1978,
Investigative urology,
B Finlayson, and
J Burns, and
A Smith, and
L Du Bois
January 2012,
Annales de biologie clinique,
B Finlayson, and
J Burns, and
A Smith, and
L Du Bois
July 1971,
Biochemical pharmacology,
B Finlayson, and
J Burns, and
A Smith, and
L Du Bois
November 1983,
American family physician,
B Finlayson, and
J Burns, and
A Smith, and
L Du Bois
January 1995,
European journal of clinical pharmacology,
B Finlayson, and
J Burns, and
A Smith, and
L Du Bois
January 1974,
Advances in experimental medicine and biology,
B Finlayson, and
J Burns, and
A Smith, and
L Du Bois
June 1994,
The Journal of pharmacy and pharmacology,
B Finlayson, and
J Burns, and
A Smith, and
L Du Bois
March 1970,
The Journal of clinical investigation,
B Finlayson, and
J Burns, and
A Smith, and
L Du Bois
May 1991,
Clinical pharmacology and therapeutics,
